Takayoshi Uchiyama
Overview
Explore the profile of Takayoshi Uchiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uchiyama T, Yokoyama A, Kuroda Y, Aoki S
J Clin Exp Hematop
. 2024 Jul;
64(3):208-215.
PMID: 39085127
In diagnosing TAFRO syndrome, lymph node histology often may not be evaluated due to inapparent lymphadenopathy. In this study, we analyzed the differences in the pathophysiology of TAFRO syndrome with...
2.
Uchiyama T, Yokoyama A, Aoki S
J Clin Exp Hematop
. 2020 Nov;
60(4):138-145.
PMID: 33148932
Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients...
3.
Suzuki T, Miyakoshi S, Nanba A, Uchiyama T, Kawamoto K, Aoki S
J Clin Exp Hematop
. 2018 Jul;
58(3):136-140.
PMID: 30012921
Ibrutinib (IBR) covalently binds to the active site of Bruton's tyrosine kinase (BTK) and is used for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Approximately 5-10% of CLL is...
4.
Iwabuchi M, Narita M, Uchiyama T, Iwaya S, Oiwa E, Nishizawa Y, et al.
Mol Med Rep
. 2015 May;
12(2):2443-50.
PMID: 25936433
The aim of the present study was to enhance the efficiency of leukemia immunotherapy by increasing the antigen-specific cytotoxic T lymphocyte-inducing ability of leukemia cells. The leukemic plasmacytoid dendritic cell...
5.
Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, et al.
Int J Oncol
. 2015 Jan;
46(4):1699-709.
PMID: 25625346
Patients with advanced stage of squamous cell carcinoma of esophagus have a poor prognosis with a lethal outcome. In order to explore the feasibility and effectiveness of dendritic cell (DC)-based...
6.
Narita M, Nishizawa Y, Iwaya S, Oiwa E, Iwabuchi M, Uchiyama T, et al.
Int Arch Allergy Immunol
. 2014 Oct;
165(1):52-60.
PMID: 25342444
Background: Ustekinumab is currently used for the treatment of psoriasis with remarkable efficiency. However, worries about the development of malignancies in ustekinumab-treated patients have not been completely resolved because of...
7.
Yamahira A, Narita M, Iwabuchi M, Uchiyama T, Iwaya S, Ohiwa R, et al.
Anticancer Res
. 2014 Jul;
34(8):4021-8.
PMID: 25075025
Background/aim: Indoleamine-2,3-dioxygenase (IDO) is a rate-limiting enzyme for tryptophan metabolism and plays an immunosuppressive role. Antigen-presenting cells, when activated, increase the expression of IDO, which results in the suppression of...
8.
Takahashi M, Elbarbary R, Watanabe N, Goto A, Kamiya D, Watabe Y, et al.
Leuk Res
. 2014 Apr;
38(7):808-15.
PMID: 24768135
tRNase-Z(L)-utilizing efficacious (TRUE) gene silencing is an RNA-mediated gene expression control technology that has therapeutic potential. This technology is based on the property of tRNase Z(L) that it can cleave...
9.
Narita M, Saito A, Kojima A, Iwabuchi M, Satoh N, Uchiyama T, et al.
Int J Med Sci
. 2012 Nov;
9(10):901-8.
PMID: 23155364
Quantification of tumor-associated mRNA extracted from blood cells/tissues containing tumor cells is used for evaluation of treatment efficacy or residual tumor cell burden in tumors including leukemia. However, this method...
10.
Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, et al.
Hematol Oncol
. 2012 Oct;
31(3):156-63.
PMID: 23108877
Lymphocytosis predominantly due to natural killer (NK) cells has been reported in nearly a half of chronic myelogenous leukemia (CML) patients who were being treated with dasatinib. Besides, dasatinib-treated patients...